MIOSTAT

What it isNon-selective cholinergic agonist resistant to cholinesterase; intraoperative miosis and glaucoma.
Why this oneIts resistance to hydrolysis gives a longer effect than acetylcholine in the eye.
What limits itSystemic absorption can cause sweating and abdominal cramps; use cautiously in patients with asthma, acute heart failure, or urinary obstruction.
Principal riskNicotinic as well as muscarinic activity, so systemic absorption causes broad cholinergic effect
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Miosis during ocular surgery; reduces IOP elevation in first 24 h after cataract surgery | Adults | No more than 0.5 mL gently instilled into anterior chamber, single intraoperative dose | Single dose (miosis maximal within 2-5 min) | 0.5 mL |
Renal Undefined
Hepatic Undefined
Available strengths
Pregnancy No adequate well-controlled studies; use only if potential benefit justifies fetal risk
Lactation Unknown whether excreted in breast milk; exercise caution in nursing women
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 0.01 % | sol | per unit | not offered |
Open Carbachol in the interactive console ↗